These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8324747)

  • 41. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
    Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
    Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
    Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
    Kuczyk MA; Serth J; Bokemeyer C; Schwede J; Herrmann R; Machtens S; Grünewald V; Höfner K; Jonas U
    Oncol Rep; 1998; 5(1):213-6. PubMed ID: 9458379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens.
    Yasunaga Y; Shin M; Fujita MQ; Nonomura N; Miki T; Okuyama A; Aozasa K
    Lab Invest; 1998 Oct; 78(10):1275-9. PubMed ID: 9800953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation.
    Ricevuto E; Ficorella C; Fusco C; Cannita K; Tessitore A; Toniato E; Gabriele A; Frati L; Marchetti P; Gulino A; Martinotti S
    Am J Pathol; 1996 Feb; 148(2):405-13. PubMed ID: 8579104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p53 molecule as a prognostic marker in human malignancies.
    Munshi A; Byrne P; Ramesh R; Freeman SM; Marrogi AJ
    J La State Med Soc; 1998 Apr; 150(4):175-8. PubMed ID: 9610072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
    Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer.
    Gu K; Mes-Masson AM; Gauthier J; Saad F
    Mol Carcinog; 1998 Mar; 21(3):164-70. PubMed ID: 9537647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives.
    Lohmann D; Ruhri C; Schmitt M; Graeff H; Höfler H
    Diagn Mol Pathol; 1993 Mar; 2(1):36-41. PubMed ID: 8287224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
    Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
    J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
    Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
    Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA polymerase beta gene mutation in human prostate cancer.
    Dobashi Y; Shuin T; Tsuruga H; Uemura H; Torigoe S; Kubota Y
    Cancer Res; 1994 Jun; 54(11):2827-9. PubMed ID: 8187060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
    Mirchandani D; Zheng J; Miller GJ; Ghosh AK; Shibata DK; Cote RJ; Roy-Burman P
    Am J Pathol; 1995 Jul; 147(1):92-101. PubMed ID: 7604888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor suppressor gene p53 mutations in human prostate cancer.
    Kubota Y; Shuin T; Uemura H; Fujinami K; Miyamoto H; Torigoe S; Dobashi Y; Kitamura H; Iwasaki Y; Danenberg K
    Prostate; 1995 Jul; 27(1):18-24. PubMed ID: 7603913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p53 mutations and overexpression in locally advanced breast cancers.
    Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F
    Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. P53 mutations in myelodysplastic syndromes.
    Ludwig L; Schulz AS; Janssen JW; Grünewald K; Bartram CR
    Leukemia; 1992 Dec; 6(12):1302-4. PubMed ID: 1453775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency and characterization of p53 mutations in clinically localized prostate cancer.
    Hall MC; Navone NM; Troncoso P; Pollack A; Zagars GK; von Eschenbach AC; Conti CJ; Chung LW
    Urology; 1995 Mar; 45(3):470-5. PubMed ID: 7879337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.